The stage dependent changes in NK cell activity and the expression of activating and inhibitory NK cell receptors in melanoma patients

Journal of Surgical Research

Volumn 171, Issue 2, 2011, Pages 637-649

  Mirjacic Martinovic, Katarina ^a   Konjević, Gordana ^a,b   Babović, Nada ^a   Inić, Momčilo ^a  

^a INSTITUTE FOR ONCOLOGY AND RADIOLOGY OF SERBIA   (Serbia)

^b UNIVERSITY OF BELGRADE   (Serbia)

Author keywords

CD158b; cytotoxicity; melanoma; NK cells; NKG2D

Indexed keywords

CD161 ANTIGEN; CD56 ANTIGEN; CHROMIUM 51; GAMMA INTERFERON; KILLER CELL IMMUNOGLOBULIN LIKE RECEPTOR 2DL1; KILLER CELL IMMUNOGLOBULIN LIKE RECEPTOR 2DL2; LYSOSOME ASSOCIATED MEMBRANE PROTEIN 1; NATURAL KILLER CELL RECEPTOR NKG2D; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGED; ARTICLE; CANCER PATIENT; CANCER STAGING; CD3+ T LYMPHOCYTE; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; LYMPHOCYTE SUBPOPULATION; MALE; MELANOMA; NATURAL KILLER CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; RADIOACTIVITY;

ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, CD3; ANTIGENS, CD56; FEMALE; FLOW CYTOMETRY; HUMANS; KILLER CELLS, NATURAL; LYMPHOCYTE ACTIVATION; LYSOSOMAL-ASSOCIATED MEMBRANE PROTEIN 1; MALE; MELANOMA; MIDDLE AGED; NEOPLASM STAGING; RECEPTORS, KIR2DL2; RECEPTORS, NATURAL KILLER CELL; SKIN NEOPLASMS; YOUNG ADULT;

EID: 81155133365     PISSN: 00224804     EISSN: 10958673     Source Type: Journal    
DOI: 10.1016/j.jss.2010.05.012     Document Type: Article

References (51)

1. M.J. Robertson, and J. Ritz Biology and clinical relevance of human natural killer cells Blood 76 1990 2421
2. J.S. Orange, and Z.K. Ballas Natural killer cells in human health and disease Clin Immunol 118 2006 1
3. M.A. Cooper, T.A. Fehniger, and M.A. Caligiuri The biology of human natural killer-cell subsets Trends Immunol 22 2001 633
4. M.A. Cooper, T.A. Fehniger, and S.C. Turner Human natural killer cells: A unique innate immunoregulatory role for the CD56(bright) subset Blood 97 2001 3146
5. S.S. Farag, and M.A. Caligiuri Human natural killer cell development and biology Blood Rev 20 2006 123
6. L.L. Lanier NK cell receptors Annu Rev Immunol 16 1998 359
7. D.B. Rosen, J. Bettadapura, and M. Alsharifi Cutting edge: Lectin-like transcript-1 is a ligand for the inhibitory human NKR-P1A receptor J Immunol 175 2005 7796
8. H. Aldemir, V. Prod'homme, and M.J. Dumaurier Cutting edge: Lectin-like transcript 1 is a ligand for the CD161 receptor J Immunol 175 2005 7791
9. R. Solana, J.G. Casado, and E. Delgado Lymphocyte activation in response to melanoma: Interaction of NK-associated receptors and their ligands Cancer Immunol Immunother 56 2007 101
10. J.D. Coudert, and W. Held The role of the NKG2D receptor for tumor immunity Semin Cancer Biol 16 2006 333
11. A.R. Mistry, and C.A. O'Callaghan Regulation of ligands for the activating receptor NKG2D Immunology 121 2007 439
12. B. Le Maux Chansac, D. Missé, and C. Richon Potentiation of NK cell-mediated cytotoxicity in human lung adenocarcinoma: Role of NKG2D-dependent pathway Int Immunol 20 2008 801
13. Y.T. Bryceson, and H.G. Ljunggren Tumor cell recognition by the NK cell activating receptor NKG2D Eur J Immunol 38 2008 2957
14. H. Tsao, M.B. Atkins, and A.J. Sober Management of cutaneous melanoma N Engl J Med 351 2004 998
15. M.R. Hussein Tumour-infiltrating lymphocytes and melanoma tumorigenesis: An insight Br J Dermatol 153 2005 18
16. C.M. Balch, A.J. Sober, and S.J. Soong AJCC Melanoma Staging Committee. The new melanoma staging system Semin Cutan Med Surg 22 2003 42
17. R.L. Brown, J.R. Ortaldo, and R.L. Griffith The proliferation and function of human mononuclear leukocytes and natural killer cells in serum-free medium J Immunol Methods 81 1985 207
18. A. Jackson, and N. Warner Preparation, staining, and analysis by flow cytometry of peripheral blood leukocytes N. Rose, H. Friedmah, J. Fahey, Manual of Clinical Laboratory Immunology 1986 American Society for Microbiology Washington DC 226
19. R.T. Costello, C. Fauriat, and S. Sivori NK cells: Innate immunity against hematological malignancies? Trends Immunol 25 2004 328
20. J.J. Kiladjian, E. Bourgeois, and I. Lobe Cytolytic function and survival of natural killer cells are severely altered in myelodysplastic syndromes Leukemia 20 2006 463
21. P.K. Epling-Burnette, F. Bai, and J.S. Painter Reduced natural killer (NK) function associated with high-risk myelodysplastic syndrome (MDS) and reduced expression of activating NK receptors Blood 109 2007 4816
22. G. Konjević, K. Mirjacić Martinović, and V. Jurisić Biomarkers of suppressed natural killer (NK) cell function in metastatic melanoma: Decreased NKG2D and increased CD158a receptors on CD3-CD16+ NK cells Biomarkers 14 2009 258
23. R. Castriconi, C. Cantoni, and M. Della Chiesa Transforming growth factor β1 inhibits expression of NKp30 and NKG2D receptors: Consequences for the NK-mediated killing of dendritic cells Proc Natl Acad Sci USA 100 2003 4120
24. W.L. Sibbitt Jr. , A.D. Bankhurst, and A.J. Jumonville Defects in natural killer cell activity and interferon response in human lung carcinoma and malignant melanoma Cancer Res 44 1984 852
25. M.G. Seidel, M. Freissmuth, and H. Pehamberger Stimulation of natural killer activity in peripheral blood lymphocytes of healthy donors and melanoma patients in vitro: Synergism between interleukin (IL)-12 and IL-15 or IL-12 and IL-2 Naunyn Schmiedebergs Arch Pharmacol 358 1998 382
26. G. Konjević, K. Mirjacić Martinović, and A. Vuletić Low expression of CD161 and NKG2D activating NK receptor is associated with impaired NK cell cytotoxicity in metastatic melanoma patients Clin Exp Metastasis 24 2007 1
27. G. Alter, J.M. Malenfant, and M. Altfeld CD107a as a functional marker for the identification of natural killer cell activity J Immunol Methods 294 2004 15
28. E. Aktas, U.C. Kucuksezer, and S. Bilgic Relationship between CD107a expression and cytotoxic activity Cell Immunol 254 2009 149
29. A. Bose, T. Chakraborty, and K. Chakraborty Dysregulation in immune functions is reflected in tumor cell cytotoxicity by peripheral blood mononuclear cells from head and neck squamous cell carcinoma patients Cancer Immun 8 2008 10
30. L. Ciszak, A. Kosmaczewska, and B. Werynska Impaired zeta chain expression and IFN-γ production in peripheral blood T and NK cells of patients with advanced lung cancer Oncol Rep 21 2009 173
31. C. López-Larrea, B. Suárez-Alvarez, and A. López-Soto The NKG2D receptor: Sensing stressed cells Trends Mol Med 14 2008 179
32. K.M. Lee, D.W. Kim, and D.S. Heo Elevated TGF-beta1 secretion and down-modulation of NKG2D underlies impaired NK cytotoxicity in cancer patients J Immunol 172 2004 7335
33. R.A. Eagle, and J. Trowsdale Promiscuity and the single receptor: NKG2D Nat Rev Immunol 7 2007 737
34. V. Groh, J. Wu, C. Yee, and T. Spies Tumor-derived soluble MIC ligands impair expression of NKG2D and T-cell activation Nature 419 2002 734
35. M.B. Fuertes, M.V. Girart, and L.L. Molinero Intracellular retention of the NKG2D ligand MHC class I chain-related gene A in human melanomas confers immune privilege and prevents NK cell-mediated cytotoxicity J Immunol 180 2008 4606
36. D. Pende, C. Cantoni, and P. Rivera Role of NKG2D in tumor cell lysis mediated by human NK cells: Cooperation with natural cytotoxicity receptors and capability of recognizing tumors of nonepithelial origin Eur J Immunol 31 2001 1076
37. C. Liu, S. Yu, and K. Zinn Murine mammary carcinoma exosomes promote tumor growth by suppression of NK cell function J Immunol 176 2006 1375
38. A. Clayton, J.P. Mitchell, and J. Court Human tumor-derived exosomes down-modulate NKG2D expression J Immunol 180 2008 7249
39. V. Pascal, N. Schleinitz, and C. Brunet Comparative analysis of NK cell subset distribution in normal and lymphoproliferative disease of granular lymphocyte conditions Eur J Immunol 34 2004 2930
40. Y. Izumi, H. Ida, and M. Huang Characterization of peripheral natural killer cells in primary Sjögren's syndrome: Impaired NK cell activity and low NK cell number J Lab Clin Med 147 2006 242
41. M. Uhrberg, N.M. Valiante, and B.P. Shum Human diversity in killer cell inhibitory receptor genes Immunity 7 1997 753
42. J. Trowsdale, and P. Parham Mini-review: Defense strategies and immunity-related genes Eur J Immunol 34 2004 7
43. M. Yawata, N. Yawata, and M. Draghi Roles for HLA and KIR polymorphisms in natural killer cell repertoire selection and modulation of effector function J Exp Med 203 2006 633
44. E. Naumova, A. Mihaylova, and M. Ivanova Impact of KIR/HLA ligand combinations on immune responses in malignant melanoma Cancer Immunol Immunother 56 2007 95
45. J.A. Campillo, J.A. Martínez-Escribano, and M.R. Moya-Quiles Natural killer receptors on CD8 T cells and natural killer cells from different HLA-C phenotypes in melanoma patients Clin Cancer Res 12 2006 4822
46. C.C. Stebbins, C. Watzl, and D.D. Billadeau Vav1 dephosphorylation by the tyrosine phosphatase SHP-1 as a mechanism for inhibition of cellular cytotoxicity Mol Cell Biol 23 2003 6291
47. C. Zhang, J. Zhang, and H. Wei Imbalance of NKG2D and its inhibitory counterparts: How does tumor escape from innate immunity? Int Immunopharmacol 5 2005 1099
48. A.K. Purdy, and K.S. Campbell Natural killer cells and cancer: Regulation by the killer cell Ig-like receptors (KIR) Cancer Biol Ther 8 2009 2211
49. S. Andersson, J.A. Malmberg, and K.J. Malmberg Tolerant and diverse natural killer cell repertoires in the absence of selection Exp Cell Res 2010 (in press)
50. J.R. Passweg, B. Huard, and J.M. Tiercy HLA and KIR polymorphisms affect NK-cell anti-tumor activity Trends Immunol 28 2007 437
51. M.A. Caligiuri Human natural killer cells Blood 112 2008 461